世界のエピジェネティクス技術市場...市場調査レポートについてご紹介

TABLE OF CONTENTS:

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT SCOPE
1.3 RESEARCH METHODOLOGY
1.4 KEY DATA POINTS FROM PRIMARY AND SECONDARY SOURCES

2 EXECUTIVE SUMMARY

3 EPIGENETICS – TECHNOLOGY LANDSCAPE ANALYSIS
3.1 TECHNOLOGY OVERVIEW
3.2 TECHNOLOGY EVOLUTION – MILESTONES IN EPIGENETICS
3.3 EPIGENETIC MECHANISMS
3.3.1 DNA METHYLATION
3.3.2 HISTONE MODIFICATIONS
3.3.3 RNA INTERFERENCE
3.4 TECHNOLOGY VALUE CHAIN ANALYSIS
3.5 APPLICATIONS
3.5.1 THERAPEUTICS
3.5.1.1 ONCOLOGY CONDITIONS
3.5.1.2 NON-ONCOLOGY INDICATIONS
3.5.1.3 PERSONALIZED MEDICINE
3.5.2 RESEARCH AND DIAGNOSTICS
3.5.2.1 GENE REGULATION STUDIES
3.5.2.2 BIOMARKER DETECTION
3.5.2.3 DRUG DISCOVERY
3.6 EPIGENETICS – TECHNOLOGY INNOVATIONS AND PRODUCTS WITH APPLICATIONS
3.7 CURRENT SCENARIO IN EPIGENETICS

4 EPIGENETICS – MARKET LANDSCAPE ANALYSIS
4.1 EPIGENETICS MARKET SIZE – POTENTIAL ADDRESSABLE MARKET
4.2 GLOBAL EPIGENETICS MARKET SEGMENTATION
4.3 GLOBAL MARKET REVENUE FORECAST (2012-2017)
4.3.1 BY GEOGRAPHY
4.3.2 BY APPLICATIONS
4.3.3 BY EPIGENETIC MECHANISMS
4.4 MARKET SHARE OF COMPANIES
4.5 MARKET DYNAMICS
4.5.1 DRIVERS
4.5.2 RESTRAINTS
4.5.3 CHALLENGES

5 TECHNOLOGY INVESTMENT POTENTIAL
5.1 INVESTOR NETWORK
5.1.1 SOME FUNDS AND INVESTMENTS BY PUBLIC FUNDING BODIES
5.1.2 SOME FUNDS AND INVESTMENTS BY NON-GOVERNMENT ORGANIZATIONS (NGOs)
5.1.3 SOME INVESTMENTS BY CORPORATE, PRIVATE AND EQUITY INVESTORS
5.1.4 INSIGHTS ON CURRENT AND FUTURE TECH-INVESTMENT TRENDS
5.1.5 FUNDING PATTERNS AND INVESTOR INCLINATION

5.2 INVESTMENT OPPORTUNITIES
5.2.1 EPIGENETIC TECHNOLOGIES AND PRODUCTS AVAILABLE FOR LICENSING & ACQUISITION FOR STAKEHOLDERS
5.2.2 ANALYSIS OF POTENTIAL APPLICATION AREAS FOR TECHNOLOGY INVESTMENT – BASED ON OPPORTUNITY STRATEGY EVALUATION (OSE) ANALYSIS

6 EPIGENETICS – TECHNOLOGY ADOPTION POTENTIAL AND DEVELOPMENT BY GEOGRAPHY
6.1 INTRODUCTION
6.2 NORTH AMERICA
6.3 EUROPE
6.4 ASIA
6.5 ROW
6.6 DEMAND SIDE ANALYSIS

7 EPIGENETICS COMPETITIVE LANDSCAPE
7.1 KEY MERGERS AND ACQUISITIONS
7.2 PARTNERSHIPS AND COLLABORATIONS
7.3 THERAPEUTIC DRUGS IN PIPELINE
7.4 WORLDWIDE CONSORTIUMS AND NETWORKS IN EPIGENETICS

8 INTELLECTUAL PROPERTY AND RESEARCH STRENGTH ANALYSIS
8.1 IP STRENGTH ANALYSIS OF EPIGENETICS BETWEEN 2008-2012
8.2 ANALYSIS OF RESEARCH STRENGTH FROM NCBI PUBMED PUBLICATIONS

9 ANALYST INSIGHTS AND RECOMMENDATIONS
9.1 ANALYST INSIGHTS
9.2 ANALYST RECOMMENDATIONS
9.3 OPEN OPPORTUNITY INVITATIONS IN THE FIELD FOR BUSINESS DEVELOPMENT

10 COMPANY PROFILES
10.1 4SC (GERMANY)
10.2 CELGENE (U.S.)
10.3 CELLCENTRIC (U.K.)
10.4 CH3 BIOSYSTEMS (U.S.)
10.5 COVARIS INC (U.S.)
10.6 EISAI CO LTD (JAPAN)
10.7 EPIONTIS (GERMANY)
10.8 EPITHERAPEUTICS (DENMARK)
10.9 EPIZYME (U.S.)
10.10 KARUS THERAPEUTICS (U.K.)
10.11 MERCK MILLIPORE (U.S.)
10.12 RIBOMED BIOTECHNOLOGIES (U.S.)

11 APPENDIX

12 GLOSSARY